What You Should Know:
- Flatiron Health, and Lifebit Biotech Ltd (UK, London; hereafter “Lifebit”), are expanding their collaboration into Japan to transform cancer care, facilitating ground breaking research by allowing for safe and secure access to real-world data (RWD).
- Building on the success of their multi-year strategic partnership, Lifebit’s pioneering federated Trusted Research Environment (TRE) technology will enable safe and secure access to Flatiron Health’s high-quality
Read More
Cancer Diagnostics
Morehouse School of Medicine Tackles Cancer Disparities with AI-Driven Research
What You Should Know:
- Manifold, an AI-powered clinical data platform, announced that Morehouse School of Medicine (MSM) will leverage their platform to modernize cancer genomics data analysis and improve collaboration among multidisciplinary stakeholders.
- With Manifold, the Institute of Translational Genomic Medicine (ITGM) at MSM is building a modern data foundation to accelerate cancer research—integrating multimodal sources like clinical outcomes, genomics, survey, and geospatial
Read More
Panalgo Partners with COTA to Enhance AI & RWD-Enabled Cancer Care
What You Should Know:
- Panalgo, a provider of healthcare data analytics solutions, has announced a partnership with COTA, an organization focused on providing real-world data (RWD) for cancer care.
- The strategic collaboration will enable COTA to make its high-quality hematologic oncology data available through Panalgo's Instant Health Data Analytics (IHD) platform.
Leveraging COTA's Real-World Data
COTA's RWD is derived from electronic health records (EHRs) and offers
Read More
CancerIQ Raises Growth Capital for Personalized Cancer Detection
What You Should Know:
- CancerIQ, a Chicago, IL-based precision health platform focused on empowering healthcare providers to personalize cancer prevention and early detection announced it has secured a growth funding package from Decathlon Capital Partners.
- While specific financial details of the transaction were not disclosed, the investment will enable CancerIQ to further develop its digital tools, introduce new offerings, and strengthen partnerships with healthcare
Read More
PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments
What You Should Know:
- PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, GenHenn Capital Venture, and existing investors. This brings the company's total funding to date to $31.5M.
- The new funding will enable PreciseDx to accelerate its growth and expand its operations. The company plans to invest in talent
Read More
Pangea Biomed Partners with Hadassah to Develop Cancer Treatment
What You Should Know:
- Pangea Biomed, the startup behind the world’s most advanced cancer response predictor, ENLIGHT, is announcing a strategic collaboration with the Sharett Institute of Oncology and Hadassah Cancer Research Institute (HCRI) at the Hadassah University Hospital Ein-Kerem and Ultima Genomics, the developer of a revolutionary architecture for high-throughput genomic sequencing.
- This partnership aims to enhance the accuracy and effectiveness of solid tumor cancer
Read More
CMS Establishes National Payment for AI Prostate Cancer Mapping
What You Should Know:
- Avenda Health, a pioneer in AI-powered prostate cancer care, announced today that the Centers for Medicare & Medicaid Services (CMS) has assigned a national payment rate for its prostate cancer mapping technology, Unfold AI.
- This significant development, alongside the establishment of a new Category III code by the American Medical Association (AMA), paves the way for broader adoption of Unfold AI and improved prostate cancer diagnosis and
Read More
Thyme Care Secures $95M to Expand Value-Based Cancer Care Platform
What You Should Know:
- Thyme Care, a leading value-based cancer care enabler raises $95M in funding capital led by Concord Health Partners, with participation from existing investors including CVS Health® Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Foresite Capital, and new investor SignalFire. The funding brings Thyme Care's total funding to $178M.
- Thyme Care is a value-based cancer care enabler focused on improving patient outcomes and
Read More
Pangea Biomed’s ENLIGHT-DP Predicts Cancer Treatment Response from Simple Scans
What You Should Know:
- Pangea Biomed, a leader in precision oncology, announced a significant breakthrough in its ENLIGHT cancer response predictor. A new study published in Nature Cancer demonstrates the effectiveness of their ENLIGHT-DP platform, revealing its ability to predict cancer treatment response across various types and drugs using only routine pathology slides.
- While these findings are promising, further validation and testing are planned for regulatory
Read More
Color and Carrum Health Partner for End-to-End Cancer Care
What You Should Know:
- Color Health, a leader in comprehensive cancer care, and Carrum Health, known for their value-based cancer treatment programs form a startegic partnership to offer employers an end-to-end cancer program.
- By providing a seamless, cost-effective, and patient-centric experience, the end-to-end cancer program empowers employers to combat rising cancer rates and improve the overall health and well-being of their workforce.
The Deadly Reality of
Read More
